Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Among authors: yakushijin k. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
Mizutani Y, Inase A, Maimaitili Y, Miyata Y, Kitao A, Matsumoto H, Kawaguchi K, Higashime A, Goto H, Kurata K, Yakushijin K, Minami H, Matsuoka H. Mizutani Y, et al. Among authors: yakushijin k. Int J Hematol. 2019 Oct;110(4):490-499. doi: 10.1007/s12185-019-02701-2. Epub 2019 Jul 8. Int J Hematol. 2019. PMID: 31286402
A Pathogenic NRAS c.38G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome.
Goto H, Yakushijin K, Adachi Y, Matsumoto H, Yamamoto K, Matsumoto S, Yamashita T, Higashime A, Kawaguchi K, Kurata K, Matsuoka H, Minami H. Goto H, et al. Among authors: yakushijin k. Intern Med. 2023 May 1;62(9):1329-1334. doi: 10.2169/internalmedicine.0174-22. Epub 2022 Sep 21. Intern Med. 2023. PMID: 36130886 Free PMC article.
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Yanagita M, et al. Among authors: yakushijin k. Clin Exp Nephrol. 2024 Feb;28(2):85-122. doi: 10.1007/s10157-023-02415-0. Epub 2023 Oct 25. Clin Exp Nephrol. 2024. PMID: 37878114 Free PMC article. No abstract available.
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Yanagita M, et al. Among authors: yakushijin k. Clin Exp Nephrol. 2024 Feb;28(2):123-124. doi: 10.1007/s10157-023-02436-9. Clin Exp Nephrol. 2024. PMID: 38070021 Free PMC article. No abstract available.
Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis.
Okamura A, Yakushijin K, Inui Y, Funakoshi Y, Kawamori Y, Shimada T, Toyoda M, Chayahara N, Kiyota N, Fujiwara Y, Mukohara T, Matsuoka H, Yamamoto K, Minami H. Okamura A, et al. Among authors: yakushijin k. Int J Hematol. 2011 Jun;93(6):765-770. doi: 10.1007/s12185-011-0852-5. Epub 2011 Apr 22. Int J Hematol. 2011. PMID: 21512728
183 results